drugset
drugset / Trial / NCT00498901

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

NCT00498901 ↗

Phase 2 Terminated 1 enrolled University of Washington National Cancer Institute (NCI) · collab
Open-labelTreatment

Summary

RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effective treatment in women with hormone-dependent breast cancer. PURPOSE: This phase II trial is studying how well giving letrozole together with goserelin or leuprolide works in treating premenopausal estrogen receptor-positive patients with stage IV breast cancer.

Timeline

Start
2007-02
Primary completion
2007-12
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified — Intramuscular
Subject Letrozole Other / unclassified — Oral
Subject Leuprolide Other / unclassified — Intramuscular

Indications

breast cancer